Antitumor activity of interleukin-21 prepared by novel refolding procedure from inclusion bodies expressed in Escherichia coli. (Q54537661)

31 May 2018

title

Antitumor activity of interleukin-21 prepared by novel refolding procedure from inclusion bodies expressed in Escherichia coli. (English)

1 reference

31 May 2018

0 references

1 reference

1 reference

Ryutaro Asano

1 reference

31 May 2018

Toshio Kudo

1 reference

31 May 2018

Koki Makabe

1 reference

31 May 2018

Kouhei Tsumoto

1 reference

31 May 2018

Izumi Kumagai

1 reference

31 May 2018

language of work or name

English

0 references

publication date

1 September 2002

1 reference

31 May 2018

published in

FEBS Letters

1 reference

31 May 2018

volume

528

1 reference

31 May 2018

issue

1-3

1 reference

31 May 2018

page(s)

70-76

1 reference

31 May 2018

Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-5793%2802%2903254-4

Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0014-5793%2802%2903254-4

"Diabodies": small bivalent and bispecific antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0014-5793%2802%2903254-4

Recombinant antibodies for cancer diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0014-5793%2802%2903254-4

Cytoplasmic and periplasmic expression of a highly basic protein, human interleukin 4, in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0014-5793%2802%2903254-4

Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0014-5793%2802%2903254-4

Structure of unfolded and refolded recombinant derived [Ala125]interleukin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0014-5793%2802%2903254-4

Purification of human interleukin-4 produced in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0014-5793%2802%2903254-4

Separate C-terminal domains of the epithelial specific brush border Na+/H+ exchanger isoform NHE3 are involved in stimulation and inhibition by protein kinases/growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0014-5793%2802%2903254-4

Application of combined reagent solution to the oxidative refolding of recombinant human interleukin 6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0014-5793%2802%2903254-4

Functional Fv fragment of an antibody specific for CD28: Fv-mediated co-stimulation of T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0014-5793%2802%2903254-4

Highly efficient recovery of functional single-chain Fv fragments from inclusion bodies overexpressed in Escherichia coli by controlled introduction of oxidizing reagent--application to a human single-chain Fv fragment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-5793%2802%2903254-4

Humanization of a mouse anti-human interleukin-6 receptor antibody comparing two methods for selecting human framework regions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-5793%2802%2903254-4

Optimized Gene Synthesis, High Level Expression, Isotopic Enrichment, and Refolding of Human Interleukin-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-5793%2802%2903254-4

Functional construction of the anti-mucin core protein (MUC1) antibody MUSE11 variable regions in a bacterial expression system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-5793%2802%2903254-4

Construction of a diabody (small recombinant bispecific antibody) using a refolding system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-5793%2802%2903254-4

Specific and effective targeting cancer immunotherapy with a combination of three bispecific antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-5793%2802%2903254-4

High level expression and refolding of mouse interleukin 4 synthesized in Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-5793%2802%2903254-4

A phase I study of recombinant interleukin 2 in melanoma patients. Toxicity and clinical effects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-5793%2802%2903254-4

IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-5793%2802%2903254-4

10.1016/S0014-5793(02)03254-4

7 January 2021

Identifiers

DOI

1 reference

31 May 2018

1 reference

31 May 2018